Tilt Biotherapeutics

TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of  solid tumors as currently achieved for CD19+ hematological tumors.

Company Growth (employees)
Type
Private
HQ
Helsinki, FI
Founded
2013
Size (employees)
9 (est)-10%
Tilt Biotherapeutics was founded in 2013 and is headquartered in Helsinki, FI

Tilt Biotherapeutics Office Locations

Tilt Biotherapeutics has an office in Helsinki
Helsinki, FI (HQ)
3 Haartmaninkatu

Tilt Biotherapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$10.6 m

Latest funding size

$10.6 m

Time since last funding

11 months
Tilt Biotherapeutics's latest funding round in December 2016 was reported to be $10.6 m. In total, Tilt Biotherapeutics has raised $10.6 m

Tilt Biotherapeutics's Web-traffic and Trends

Tilt Biotherapeutics Online and Social Media Presence

Tilt Biotherapeutics Company Life and Culture

You may also be interested in